“Esophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia. This is the central finding of a recent study conducted at the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital. The study has recently been published in the European Journal of Cancer Surgery.
Esophageal cancer is the eighth most common type of cancer and sixth most common cause of death from cancer in Austria. According to “Statistik Austria,” approximately 420 people develop this type of cancer every year. This means that esophageal cancer is a rare form of cancer but the number of cases has grown rapidly over the past few years. The number of cases in men has risen sixfold and has quadrupled in women, men being more likely to develop this type of cancer than women.
Esophageal cancer is among the fastest and deadliest cancers in the United States and western world. In 2017, an estimated 16,940 will be diagnosed with esophageal cancer and there will be an estimated 15,690 deaths from esophageal cancer, in the United States.¹ Only 18.4% of patients diagnosed with esophageal cancer will survive 5(+) years.
Apart from smoking and high alcohol consumption, risk factors for esophageal cancer also include gastro-esophageal reflux disease and the resulting cell changes in the lower part of the oesophagus (Barrett metaplasia). The standard treatment for patients in which the tumour is advanced but not yet metastasised, is to give chemotherapy or a combination of chemotherapy and radiotherapy prior to surgery (multimodal therapy). In local carcinomas that are not advanced, surgery is the treatment of choice.
Nutrition and exercise affect chances of survival
In their study, experts in stomach and esophageal cancer from the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital (CCC GET-Unit, Head: Sebastian Schoppmann) investigated to what extent sarcopenia and body composition changed during multimodal therapy and whether this has any influence upon long-term survival. The results show that patients who suffered sarcopenia (loss of muscle mass below a defined threshold) at any time during treatment had a poorer prognosis for survival: on average, their period of survival was 32 months shorter than that of patients who were not diagnosed with sarcopenia. Sarcopenia was therefore identified as an independent risk factor.
Says Matthias Paireder, Department of Surgery (Head: Michael Gnant) of MedUni Vienna and Vienna General Hospital, member of the CCC-GET and lead author of the study: “Sarcopenia is not necessarily a side effect of chemotherapy. Many patients were already sarcopenic before the treatment and there was no significant progression of sarcopenia during treatment. The reasons for this loss of general muscle mass are poor nutrition and lack of exercise.”
New study planned
In a new study, the team headed up by Paireder and Schoppmann will investigate whether a programme that includes nutritional advice and physical training could significantly increase long-term survival for esophageal cancer patients.”
Materials above provided by Medical University of Vienna. Editor Note: Content may be edited.
Medical University of Vienna. “Esophageal cancer: Loss of muscle mass represents a significant risk to survival.” ScienceDaily. ScienceDaily, 14 February 2017.
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.